Literature DB >> 21568357

Health technology funding decision-making processes around the world: the same, yet different.

Tania Stafinski1, Devidas Menon, Donald J Philippon, Christopher McCabe.   

Abstract

All healthcare systems routinely make resource allocation decisions that trade off potential health gains to different patient populations. However, when such trade-offs relate to the introduction of new, promising health technologies, perceived 'winners' and 'losers' are more apparent. In recent years, public scrutiny over such decisions has intensified, raising the need to better understand how they are currently made and how they might be improved. The objective of this paper is to critically review and compare current processes for making health technology funding decisions at the regional, state/provincial and national level in 20 countries. A comprehensive search for published, peer-reviewed and grey literature describing actual national, state/provincial and regional/institutional technology decision-making processes was conducted. Information was extracted by two independent reviewers and tabulated to facilitate qualitative comparative analyses. To identify strengths and weaknesses of processes identified, websites of corresponding organizations were searched for commissioned reviews/evaluations, which were subsequently analysed using standard qualitative methods. A total of 21 national, four provincial/state and six regional/institutional-level processes were found. Although information on each one varied, they could be grouped into four sequential categories: (i) identification of the decision problem; (ii) information inputs; (iii) elements of the decision-making process; and (iv) public accountability and decision implementation. While information requirements of all processes appeared substantial and decision-making factors comprehensive, the way in which they were utilized was often unclear, as were approaches used to incorporate social values or equity arguments into decisions. A comprehensive inventory of approaches to implementing the four main components of all technology funding decision-making processes was compiled, from which areas for future work or research aimed at improving the acceptability of decisions were identified. They include the explication of decision criteria and social values underpinning processes.

Entities:  

Mesh:

Year:  2011        PMID: 21568357     DOI: 10.2165/11586420-000000000-00000

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  65 in total

1.  Managing public payment for high-cost, high-benefit treatment: enzyme replacement therapy for Gaucher's disease in Ontario.

Authors:  J T Clarke; D Amato; R B Deber
Journal:  CMAJ       Date:  2001-09-04       Impact factor: 8.262

2.  National Institute for Clinical Excellence and its value judgments.

Authors:  Michael D Rawlins; Anthony J Culyer
Journal:  BMJ       Date:  2004-07-24

3.  Prioritizing health-care funding.

Authors:  J L O'Donnell; D Smyth; C Frampton
Journal:  Intern Med J       Date:  2005-07       Impact factor: 2.048

4.  Regulating the Dutch pharmaceutical market: improving efficiency or controlling costs?

Authors:  Peter de Wolf; Werner B F Brouwer; Frans F H Rutten
Journal:  Int J Health Plann Manage       Date:  2005 Oct-Dec

5.  Centralized drug review processes in Australia, Canada, New Zealand, and the United kingdom.

Authors:  Steven G Morgan; Meghan McMahon; Craig Mitton; Elizabeth Roughead; Ray Kirk; Panos Kanavos; Devidas Menon
Journal:  Health Aff (Millwood)       Date:  2006 Mar-Apr       Impact factor: 6.301

6.  Public funding of new cancer drugs: Is NICE getting nastier?

Authors:  Anne R Mason; Michael F Drummond
Journal:  Eur J Cancer       Date:  2009-01-08       Impact factor: 9.162

7.  A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden.

Authors:  Ulf Persson; Michael Willis; Knut Odegaard
Journal:  Eur J Health Econ       Date:  2009-07-29

8.  Comparative effectiveness research and evidence-based health policy: experience from four countries.

Authors:  Kalipso Chalkidou; Sean Tunis; Ruth Lopert; Lise Rochaix; Peter T Sawicki; Mona Nasser; Bertrand Xerri
Journal:  Milbank Q       Date:  2009-06       Impact factor: 4.911

9.  Reimbursement systems, organisational forms and patient selection: evidence from day surgery in Norway.

Authors:  Pål E Martinussen; Terje P Hagen
Journal:  Health Econ Policy Law       Date:  2009-02-25

10.  Impact analysis of the discontinuation of reimbursement: the case of oral contraceptives.

Authors:  Pieter Stolk; Sebastian Schneeweiss; Hubert G M Leufkens; Eibert R Heerdink
Journal:  Contraception       Date:  2008-08-28       Impact factor: 3.375

View more
  29 in total

1.  Role of centralized review processes for making reimbursement decisions on new health technologies in Europe.

Authors:  Tania Stafinski; Devidas Menon; Caroline Davis; Christopher McCabe
Journal:  Clinicoecon Outcomes Res       Date:  2011-08-30

2.  To fund or not to fund: development of a decision-making framework for the coverage of new health technologies.

Authors:  Tania Stafinski; Devidas Menon; Christopher McCabe; Donald J Philippon
Journal:  Pharmacoeconomics       Date:  2011-09       Impact factor: 4.981

Review 3.  Societal values in the allocation of healthcare resources: is it all about the health gain?

Authors:  Tania Stafinski; Devidas Menon; Deborah Marshall; Timothy Caulfield
Journal:  Patient       Date:  2011       Impact factor: 3.883

4.  Analysing coverage decision-making: opening Pandora's box?

Authors:  Katharina Elisabeth Fischer; Reiner Leidl
Journal:  Eur J Health Econ       Date:  2014-02-06

5.  Transparency in reimbursement decisions: in whose best interest?

Authors:  Tania Stafinski; Devidas Menon
Journal:  Pharmacoeconomics       Date:  2014-08       Impact factor: 4.981

Review 6.  Public drug policy for children in Canada.

Authors:  Avram E Denburg; Wendy J Ungar; Mark Greenberg
Journal:  CMAJ       Date:  2017-07-31       Impact factor: 8.262

7.  Revealed and Stated Preferences of Decision Makers for Priority Setting in Health Technology Assessment: A Systematic Review.

Authors:  Peter Ghijben; Yuanyuan Gu; Emily Lancsar; Silva Zavarsek
Journal:  Pharmacoeconomics       Date:  2018-03       Impact factor: 4.981

Review 8.  A Systematic Review Comparing the Acceptability, Validity and Concordance of Discrete Choice Experiments and Best-Worst Scaling for Eliciting Preferences in Healthcare.

Authors:  Jennifer A Whitty; Ana Sofia Oliveira Gonçalves
Journal:  Patient       Date:  2018-06       Impact factor: 3.883

Review 9.  A National Approach to Reimbursement Decision-Making on Drugs for Rare Diseases in Canada? Insights from Across the Ponds.

Authors:  Hilary Short; Tania Stafinski; Devidas Menon
Journal:  Healthc Policy       Date:  2015-05

10.  Assessing the impact of deliberative processes on the views of participants: is it 'in one ear and out the other'?

Authors:  Tania Stafinski; Devidas Menon; Yutaka Yasui
Journal:  Health Expect       Date:  2012-02-02       Impact factor: 3.377

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.